JANUARY 13, 2021
CTTI Project: Clinical Trial Issues Related to COVID-19
Meeting Overview:
CTTI hosted The Fastest Path to Effective COVID-19 Treatments: Using Master Protocol Studies Public Summit on Wed., Jan. 13. The summit, conducted as a webinar and moderated by Pamela Tenaerts, CTTI, included a welcome from Janet Woodcock, Operation Warp Speed; a call-to-action from Robert M. Califf, Verily and Google Health; and panel discussions moderated by Ester Krofah, FasterCures, and Mark McClellan, Duke-Margolis Center for Health Policy. The panel focused on solutions related to scaling master protocols, including:
- Overcoming barriers to starting up sites
- Increasing participants at existing sites
- Using the COVID experience to inform our preparedness for future pandemics
The public summit also addressed the status of COVID-19 clinical trials, including results from a recent CTTI analysis of data from ClinicalTrials.gov and findings of a pre-summit survey that offered best practices and insights from those involved in COVID-19 treatment master protocols, specifically those setting up new sites and recruiting participants at existing sites.
This public summit is part of a collaborative effort with the Duke-Margolis Center for Health Policy at Duke University and FasterCures, a Center of the Milken Institute.
Articles of Interest
- Duke-Margolis Paper Details Strategies to Treat COVID-19
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both (The New England Journal of Medicine)
- Complete, Rapid Reporting of Clinical Trials: A Necessary Component of the Pandemic Response (Medium)
Master Protocol COVID Treatment Resources
- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)
- I-SPY COVID Trial
- RECOVERY - Randomised Evaluation of COVID-19 Therapy
- REMAP-CAP: A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia
- “Solidarity” Clinical Trial for COVID-19 Treatments
The views and opinions expressed in this presentation are those of the individual presenter and should not be attributed to the Clinical Trials Transformation Initiative, or any organization with which the presenter is employed or affiliated.
